Cancer Research

Clay Siegall at his mission to steer Seattle Genetics to greater heights.

Clay Siegall at his mission to steer Seattle Genetics to greater heights.

The company has been for long indulged in the study of the human antibodies. They have also been involved in genetically producing antibodies and supplying them in the form of drugs. As a symbol of their interest, there is a green triangle at the entrance of their building that symbolizes the human antibodies. The firm was started in 1998.

With this venture, Seattle Genetics and its neighboring communities are hoping to hit more significant levels in the biotechnical field. As per now, Seattle Genetics is the most critical biotech firm in Washington, DC. It has over 900 members of staff. It is though expected to add about 200 staff members by the end of this year. The firm’s net worth is at $10 billion. The company is striving to move to biopharma. It is mainly focused on conducting research.

The company has a drug called Adcetris. It was developed to treat Hodgkin Lymphoma. The drug is still not yet released to the market as it under waits approval.

The corporate is chaired by Clay Siegall. He is also the president and a co-founder of the firm. He said that the company is diversifying globally. He recently led the company in opening a branch in Switzerland, Africa. He also noted that their drugs are mainly in line with treating the various types of cancer. However, Siegall is determined to steer the company into exploring other biotech fields other than oncology.

Siegall had set aside. $2 billion into gaining worldwide right to release a cancer drug to the market. After some complications with the manufacturing company of the drug in question, Siegall withdrew from the commitment. He has also led the company in conducting public fundraisings to gain the necessary capital needed for development of drugs. The firm’s major fundraising was when they were raising money for their drug, Adcetris. They raised over $500 million for the drug.

Before the establishment of Seattle Genetics, Clay Siegal attended the University of Maryland. He graduated with a Bachelor’s degree in Zoology. He later attended the George Washington University where he acquired a doctorate in Genetics. He has worked in association with a pharmaceutical firm called Bristol- Myers Squibb Pharmaceutical Research Institute. He was also employed at the National Institute of Health as well as working for the National Cancer Institute. Aside from his well- known career, Mr. Siegall is an author. He has written and published more than 70 books with 15 patents.

Siegall has been successful as an entrepreneur. When questioned of his success, he quoted an old mentor of his who taught him to never accept rejection in his career.